PRQR
vs
S&P 500
PRQR
S&P 500
Over the past 12 months, PRQR has underperformed S&P 500, delivering a return of -32% compared to the S&P 500's +13% growth.
Stocks Performance
PRQR vs S&P 500
Performance Gap
PRQR vs S&P 500
Performance By Year
PRQR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ProQR Therapeutics NV
Glance View
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).